Stockscreener 앱 받기
57.08
2.79%
1.55
시간 외 거래:
57.60
0.52
+0.91%
Exelixis Inc 주식(EXEL)의 최신 뉴스
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Canada
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Santhera Pharmaceuticals Holding (OtherSPHDF) - The Globe and Mail
Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says - Moomoo
UBS raises Exelixis stock price target to $52 on pipeline outlook - Investing.com
EXEL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $56 - GuruFocus
H.C. Wainwright reiterates Exelixis stock rating at Buy, $56 target By Investing.com - Investing.com South Africa
Analyst recommendations: Adobe, AA, Nike, Exelixis… - marketscreener.com
What Does Truist’s New Analyst Think About Exelixis (EXEL) and Its Next-Generation Cancer Drug? - Yahoo Finance
Exelixis | 4: Statement of changes in beneficial ownership of securities-Officer Aftab Dana - Moomoo
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector - ChartMill
Seven Fleet Capital Management LP's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Exelixis, Inc.(NasdaqGS: EXEL) dropped from Russell 1000 Defensive Index - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Biotechnology Leader with Robust Revenue Growth and High ROE - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Price to sales forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Enterprise value to EBITDA forward of Exelixis, Inc. – GETTEX:EX9 - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Exelixis falls as final analysis of zanzalintinib Phase 3 data disappoints - MSN
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib - MSN
Exelixis stock reaches all-time high of 53.97 USD By Investing.com - Investing.com South Africa
Exelixis stock reaches all-time high of 53.97 USD - Investing.com
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Actuals & Estimates (BMFBOVESPA:E2XE34) - TradingView
Enterprise value to revenue forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Liquidity Mapping Around (EXEL) Price Events - Stock Traders Daily
Price to sales forward of Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh – BMFBOVESPA:E2XE34 - TradingView
Exelixis, Inc. Actuals & Estimates (NASDAQ:EXEL) - TradingView
EXEL Downgraded by Truist Securities -- Price Target Raised to $54 - GuruFocus
EXEL Forecast — Price Target — Prediction for 2027 - TradingView
Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh - TradingView
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday - Benzinga
EX9 Forecast — Price Target — Prediction for 2027 - TradingView
Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty - Investing.com South Africa
Truist Financial Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $54 - Moomoo
Exelixis, Inc. (EXEL) latest stock news and headlines - Yahoo Finance UK
EXELIXIS INC : TRUIST SECURITIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $54 FROM $51 - Moomoo
Price to earnings forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
EXEL Maintained by Citizens -- Price Target Raised to $55.00 - GuruFocus
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - MarketBeat
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo! Finance Canada
BofA Securities Maintains Exelixis(EXEL.US) With Sell Rating, Maintains Target Price $41 - Moomoo
Morgan Stanley reiterates Exelixis stock rating on mixed trial data By Investing.com - Investing.com India
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst - Benzinga
Morgan Stanley reiterates Exelixis stock rating on mixed trial data - Investing.com
Exelixis reports mixed results from colorectal cancer trial - Investing.com UK
Exelixis (EXEL) Shares Decline After Trial Analysis Shows No Sta - GuruFocus
Exelixis (EXEL) Reports Phase 3 Trial Results for Cancer Treatme - GuruFocus
1.17%
2.48%
자본화:
|
볼륨(24시간):